Ophthatalmogy, new eye drops from NTC for post-cataract therapy

The innovative eye drops based on levofloxacin and dexamethasone in fixed combination developed by NTC is now also available in Mexico and Southeast Asia (Thailand, Singapore, Philippines, Hong Kong)

To date, it is registered in more than 40 countries

To date, it is registered in more than 40 countries globally, and marketing rights have been granted by the Italian company in more than 80 countries

The drug, with only 28 drops in a week, reduces exposure to antibiotic therapy while maintaining unchanged control of the onset of infection and treatment of inflammation in post-cataract patients

Milan, Oct. 26, 2022 – NTC S.r.l., an Italian company specializing in pharmaceutical research and development, announces the registration in Mexico and Southeast Asia (Thailand, Singapore, Philippines, Hong Kong) of the first fixed combination in eye drops of a quinolone antibiotic – levofloxacin &#8211 and a steroidal anti-inflammatory – dexamethasone -, which, by reducing the time of antibiotic administration from 14 to 7 days, is intended to represent an innovative therapeutic solution for the prevention of infection and control of inflammation associated with’cataract surgery in adults.

“The efficacy of this eye drops has been demonstrated with the LEADER7 study, which showed that the use of levofloxacin/dexamethasone, 4 drops per day for seven days, followed if necessary, in the clinician’s judgment, by dexamethasone alone for an additional seven days, is for us clinicians a new benchmark in cataract therapy,” comments Francesco Bandello, Director Unit of Ophthalmology, IRCCS Ospedale San Raffaele, Milan, coordinator of the study. “This is a huge advance in post-cataract care; in fact, patients can now have a single eye drop that fights the onset of infection and controls inflammation, and, most importantly, halves the exposure time to antibiotics.”.

Using the antibiotic for a shorter time

“Using the antibiotic for a shorter time is an important milestone in the fight against antibiotic resistance, a phenomenon that is unfortunately very common especially in ophthalmology where we have little availability and obsolete therapies,” continues Antonio Marino, Director U.O.C. Garibaldi Hospital Ophthalmology of Catania, Italy. “In this context, the new fixed combination represents a breakthrough in the post-surgical management of cataracts; the reduction in treatment time from 14 to 7 days ensures both better therapeutic adherence by patients, who are mostly elderly, and, at the same time, lowers the likelihood of the emergence of resistance.”.

To date, the eye drops developed by NTC with the support of Italian ophthalmologists is registered in more than 40 countries globally, and marketing rights have been granted by the company in more than 80 countries.

“NTC has always been very active in the fight against antibiotic resistance, and we are delighted with the continued international expansion of this product. To see a product conceived and developed in Italy have an almost global expansion is a source of great pride for us. We hope that thanks to this achievement people undergoing cataract surgery will benefit from this innovative drug in more and more areas of the world,” concludes Riccardo Carbucicchio, CEO of NTC.